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Summary Approximately one million children die from malaria each year. A recently approved artemisinin-based tablet, Coartem (co-artemether), comprising
artemether 120 mg plus lumefantrine 20 mg, given in four doses, provides effective antimalarial treatment for children in many sub-Saharan countries. However,
this regimen is considered insufﬁcient for non-immune infants and in areas where
multidrug-resistant Plasmodium falciparum predominates. This open-label study assessed the efﬁcacy and safety of co-artemether administered to 310 African children
weighing 5—25 kg, with acute, uncomplicated falciparum malaria. Six doses of coartemether were given over 3 days, with follow-up at 7, 14 and 28 days. Treatment
rapidly cleared parasitemia and fever. The overall 28-day cure rate was 86.5%, and
93.9% when corrected by PCR for reinfection. Cure rates at 7 and 14 days exceeded
97.0% (uncorrected) and, on day 28, were similar in infants (5—<10 kg) previously exposed to malaria infection (partially immune: 88.6% uncorrected; 93.3% corrected),
and in those who were non-immune (82.5% uncorrected; 95.0% corrected). Adverse
events were mostly mild. There was no electrocardiographic evidence of cardiotoxicity. The co-artemether six-dose regimen, treating acute uncomplicated falciparum
malaria in African children, achieved rapid parasite clearance and a high cure rate.
Treatment was generally safe and well tolerated.
© 2005 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd.
All rights reserved.
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1. Introduction
Malaria is the world’s most important parasitic
disease, especially when Plasmodium falciparum
is the causative agent. Most of the burden of
falciparum malaria is borne by small children
in sub-Saharan Africa. Although most cases are
uncomplicated, falciparum malaria can evolve
into a severe, complicated and potentially fatal
form, especially in young children. Malaria kills
approximately one million children each year
(Fischer and Bialek, 2002).
In many regions of the world, malaria parasites
have become unresponsive to conventional antimalarial drugs. Many antimalarial drugs have been
associated with unsatisfactory efﬁcacy, tolerability
and safety proﬁles, as well as complicated and
expensive dosage regimens. Consequently, there is
an urgent need for new antimalarial drugs that are
effective, safe and affordable.
This study was designed, in partnership with the
WHO, to assess the efﬁcacy, safety and tolerability
of the only artemisinin-based, ﬁxed-combination
tablet of two drugs (20 mg artemether and 120 mg
lumefantrine [co-artemether, Coartem® ]) in
African infants and children, with a bodyweight as
low as 5 kg, suffering from acute, uncomplicated
falciparum malaria. The co-formulation of an
artemisinin derivative combined with another
antimalarial drug was designed to improve efﬁcacy
and compliance, and minimize selection of drugresistant parasite strains (White and Olliaro, 1996).
Artemisinin derivatives are considered to be an
integral part of the ‘Roll Back Malaria’ partnership
(WHO, 2000). Artemether was used in this study
because it exerts rapid schizontocidal effects.
However, the agent is rapidly eliminated (Lefèvre
and Thomsen, 1999), and recrudescence occurs
frequently when artemether is given alone for less
than 7 days (Bunnag et al., 1991). Artemether was
therefore combined with lumefantrine, which has
a much longer half-life, producing a low recrudescence rate (Ezzet et al., 1998). Co-artemether
is designed to provide a rapid onset of action,
a long duration of effect and a high cure rate.
As co-artemether is a ﬁxed combination and is
effective when given in a 2- or 3-day regimen,
compliance is likely to be improved as compared
with free combinations of loose tablets requiring
longer treatment periods.
The four dose regimen of co-artemether has
been shown to be effective, in terms of the 28-day
cure rate, in regions where P. falciparum is not
multidrug-resistant and patients are partially immune (Kshirsagar et al., 2000). However, in areas
where the parasite is drug-resistant, a six-dose
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schedule is required to produce similar cure rates.
Studies in Southeast Asia where plasmodial resistance to antimalarial drugs is common, have shown
that the six-dose regimen is more effective than
the four-dose regimen, while remaining equally
safe and well tolerated (Lefèvre et al., 2001;
Van Vugt et al., 1999, 2000). While the four-dose
regimen has been used safely and effectively in
children of all ages, the six-dose regimen has,
to date, only been used in studies of children
weighing more than10 kg (Lefèvre et al., 2001).
The primary aim of the study was to assess the
safety of a six-dose regimen (6 or 12 tablets) of
co-artemether administered for 3 days to patients
under 10 years of age weighing 5—25 kg, suffering
from acute, uncomplicated falciparum malaria. The
secondary objective was to assess the efﬁcacy of
this regimen, particularly for non-immune infants
(5—<10 kg).

2. Materials and methods
2.1. Study design
No existing medication was approved for a direct
comparison, so an open-label, non-comparative,
multicenter study was used. Hospitalized children
(5—25 kg) in three centers (in Kenya, Nigeria and
Tanzania) were allocated to one of three bodyweight groups: 5—<10 kg (infants) or 10—<15 kg,
each given six doses of one co-artemether tablet;
or 15—25 kg, each given six doses of two coartemether tablets. Key inclusion criteria were:
microscopy-conﬁrmed P. falciparum malaria with
parasitemia
of
1000—100 000 parasites/mm3 ;
◦
fever (≥37.5 C); and bodyweight of 5—25 kg.
Key exclusion criteria were: severe malaria
or danger signs of severe malaria; other Plasmodium infection; use of any drug known to
inﬂuence cardiac function (e.g. halofantrine)
within four weeks before screening; and requirement for continuation of other treatment for
malaria.
Doses were administered, under nurse or doctor supervision, at 0, 8, 24, 36, 48 and 60 hours.
Tablets were given with food or drink (preferably
milk) whenever possible. In children who were unable to swallow tablets, the tablets were crushed
and suspended in sterile water for dosing. Clinical evaluations, including parasite counts, were
made at 8 hours then on days 1, 2, 3, 7, 14 and
28. Boys and non-menarche girls (5—25 kg) suffering
from acute, uncomplicated P. falciparum malaria
(conﬁrmed microscopically by Giemsa-stained thick
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ﬁlm; 103 —105 parasites/mm3 ) were included if
their axillary temperature exceeded 37.5 ◦ C.
Malaria transmission intensity is considered high
at each of the three study sites. In Nigeria, the
study was conducted in Ibadan, a hyperendemic
area where malaria transmission occurs all year
round, with a major peak during the rainy season
(June—September) (Salako et al., 1990). In Tanzania, the study was conducted at Kisarawe District
Hospital on the East Coast in a rural area considered
holoendemic for malaria transmission as well as at
Kiliﬁ in Kenya where the average incidence is about
1.5 to 2 episodes of malaria per year (Nyakeriga et
al., 2004).
The Institutional Review Board of the respective
study centers and the Scientiﬁc Committee on Research in Human Subjects of the WHO reviewed and
approved the study protocol. The study ensured adherence to Good Clinical Practice and was carried
out in accordance with the Declaration of Helsinki
and directives regarding the rules governing medicinal products in the European Community and the
United States Code of Federal Regulations dealing
with clinical studies.

for cure rates are described as uncorrected or corrected.

2.2. Discontinuation of treatment
Adverse events, unsatisfactory therapeutic effect, loss of patient to follow-up, patient noncompliance or consent withdrawal were criteria
for discontinuation. All discontinued patients were
followed-up for 28 days for safety assessments,
where possible.

2.3. Rescue treatment
If vomiting of the replacement dose (of a vomited
initial dose) within 2 hours of its intake occurred,
study treatment was stopped and rescue treatment
(with a locally effective antimalarial drug such as
amodiaquine) was used.

2.4. Efﬁcacy assessments
Treatment efﬁcacy was determined based on parasitological cure rates at days 7, 14 and 28, by the
times to parasite and fever clearance; and from the
proportion of patients without gametocytes.
Recrudescence denoted clinical recurrence of
malaria after the initial clearance of parasites from
the circulation. Parasite reappearance was interpreted as either true recrudescence (with relapse
caused by the same parasite) or a new infection,
depending on PCR analysis (Henning et al., 1999;
Snounou and Beck, 1998). Thus, treatment efﬁcacy

2.5. Safety assessments
All adverse events were monitored and recorded.
Treatment-emergent symptoms of malaria were deﬁned as adverse events occurring anew or worsening from baseline, but occurring before recurrence
of parasitemia.

2.6. Safety evaluation
Assessment of possible treatment-related adverse
events during acute disease is difﬁcult, due to the
background dominance of malaria-related signs and
symptoms. Malaria clinical features were therefore
recorded at baseline, during treatment, and during
the three follow-up visits.

2.7. Electrocardiogram evaluation
A standard 12-lead electrocardiogram, including
QTc interval as the principal measure, was qualitatively analyzed at baseline and on day 3.
Both primary data and changes from baseline
were derived from an independent, blinded review of electrocardiographic results. Corrected
QTc interval values were calculated
according to
√
Bazett’s formula (QTc
=
QT/
RR)
and
Fridericia’s
√
formula (QTc = QT/3 RR msec) and, for males and
females respectively, were classiﬁed as normal
(<430 and <450 msec), borderline (431—450 and
451—470 msec) or prolonged (>450 and >470 msec).

2.8. Statistical methods
Data from the three centers were combined, analyzed and summarized for patients in the three
bodyweight groups, after completion of the 28day trial period. Safety and intention-to-treat (ITT)
populations included all patients who had received
at least one dose of co-artemether. The per protocol (PP) population comprised ITT patients who received all six doses of medication and who adhered
to the study protocol.
All efﬁcacy analyses were performed on the ITT
population, with supportive analyses on the PP population. For each cure rate (at days 7, 14 and 28),
the simple proportion of cured patients and 95%
conﬁdence intervals were calculated using exact
Pearson—Clopper limits. For time to parasite and
fever clearance, the median and 95% conﬁdence
intervals were calculated using the Kaplan—Meier
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method. The inﬂuence of selected baseline characteristics on cure rates was evaluated by a logistic
regression analysis modeling failure. Cox’s proportional hazard regression analysis was performed to
evaluate the time to parasite and fever clearance.

3. Results
3.1. Patient disposition and demographic
data
In total, 310 patients were enrolled in the study (ITT
population). The distribution of patients between
study sites was: Kenya 107 patients, Nigeria 103
patients, and Tanzania 100 patients. Four patients
discontinued treatment prematurely, one due to an
adverse event (urticaria), two withdrew consent,
and one due to a protocol violation. Three patients
completed treatment but discontinued follow-up;
Table 1

one died of gastroenteritis and two were lost to
follow-up (Table 1).
Major protocol violations were recorded in 19
children for the following reasons: at least one
missing parasite count (n = 7); fewer than six doses
of study medication taken (n = 4); other antimalarial medication taken during the study (n = 4); parasite counts <103 or >1.4 × 105 /mm3 at baseline
(n = 3); and no replacement dose given after vomiting within 2 hours of dosing (n = 1).
The gender distribution was approximately
equal for the ITT population and for each bodyweight group (Table 1). Almost all the patients
(306/310, 99%) received the full, six-dose course of
co-artemether treatment. Vomiting was uncommon
and occurred most frequently in the infant group
(5—<10 kg, 22/154, 14.3%). Most of the children
who vomited did so after only a single dose. Only
two infants (0.6%) required rescue medication
because of vomiting of the drug. In total, 34/310
(11%) of the patients required further treatment

Patient disposition and demographic data (intention-to-treat population)
Bodyweight group

Total

5—<10 kg

10—<15 kg

15—≤25 kg

Patients: n (%)
Enrolled and treated
Discontinued treatment
Discontinued during follow-up

154 (100)
3 (1.9)
1 (0.6)

110 (100)
1 (0.9)
2 (1.8)

46 (100)
0
0

310 (100)
4 (1.3)
3 (1.0)

Study site: n (%)
Kenya
Nigeria
Tanzania

54 (35.1)
50 (32.5)
50 (32.5)

38 (34.5)
37 (33.6)
35 (31.8)

15 (32.6)
16 (34.8)
15 (32.6)

107 (34.5)
103 (33.2)
100 (32.2)

Sex: n (%)
Male
Female

77 (50.0)
77 (50.0)

60 (54.5)
50 (45.5)

24 (52.2)
22 (47.8)

161 (51.9)
149 (48.1)

Age (years)
Median
Range

1.1
0.2—3.1

2.8
0.8—6.8

6.1
2.9—9.9

2.0
0.2—9.9

Bodyweight (kg)
Median
Range

8.3
5.0—9.9

12.0
10.0—14.5

18.0
15.0—25.0

10.0
5.0—25.0

Immune status: n (%)
Partial
Non-immune
Immune
Unavailable

105
40
8
1

Parasite density (no./mm3 )
Median
Range

17 581
1080—100 000

20 929
1373—137 760

14 726
1000—104 919

18 488
1000—137 760

Body temperature (◦ C)
Median
Range

38.5
37.5—40.9

38.5
37.5—40.9

38.8
37.6—40.1

38.5
37.5—40.9

(68.2)
(26.0)
(5.2)
(0.6)
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because of parasite recurrence; the majority
(26/310, 8.4%) received amodiaquine.

233/310 (76%) of the children took acetaminophen
(paracetamol) during the study.
Only a very low proportion of patients, 26/310
(8.4%), had gametocytes on days 0—3. None of the
children had gametocytes after day 14.
Symptoms of malaria disappeared in almost all
patients during the ﬁrst three days of the study.

3.2. Cure rates with co-artemether
Both 7- and 14-day uncorrected cure rates were
greater than 97% for the ITT population (Table 2),
and attained 100% for the PP population in all bodyweight groups. The overall 28-day cure rate for
the ITT population, corrected for reinfection, was
291/310 (93.9%).
Between days 14 and 28, malaria became
evident again in 34/310 (11%) children. New
infections, distinguished from true recrudescence
by the PCR ﬁndings, developed in 23/310 (7.4%)
and true recrudescence was documented in 11/310
(3.5%). Cure rates were independent of baseline
parasite densities, body temperature, study site,
age, sex, bodyweight (despite the relatively higher
mg/kg doses received by the 5—<10 kg group), or
previous malaria infection.

3.3. Times to parasite and fever clearance
The median times to parasite clearance ranged
from 24 to 36 hours. An exploratory analysis (Cox’s
proportional hazard regression) showed that there
was no statistically signiﬁcant effect of baseline
parasite density, body temperature, age, sex, bodyweight or previous malaria infection on parasite
clearance rates. Overall, 170/305 (55.7%) patients
achieved clearance within 24 hours, and 302/307
(98.4%) within 48 hours. The median time to fever
clearance was less than 8 hours in all groups;

Table 2

3.4. Efﬁcacy in non-immune infants
The malaria immunity status of infants weighing
5—<10 kg was assessed before the start of treatment. An infant was considered partially immune
if he/she lived in an endemic area with high
prevalence of malarial infection, or had suffered
a previous attack of malaria; otherwise, infants
were considered to be non-immune. Forty of the
154 infants (26%) had not suffered from a known
previous malaria infection, and were considered
to be non-immune at baseline. Uncorrected cure
rates for days 7 and 14 in these non-immune infants
(5—<10 kg) were 100.0%. The 28-day uncorrected
cure rate was 82.5% (33/40), compared with
88.6% (93/105) in partially immune infants. When
corrected by PCR results, the 28-day cure rate for
the ITT non-immune population was 95.0% (38/40),
compared with 93.3% (98/105) for the partially
immune ITT population.

3.5. Adverse events
The most common adverse events, irrespective of
cause, reported in >10% of the patients overall
included cough, anemia, anorexia, vomiting and

Parasitological cure rates

Population

Bodyweight group

Cure rate

5—<10 kg
(n =154)

10—<15 kg
(n = 110)

15—≤25 kg
(n = 46)

(n = 310)

ITT population
7-day
14-day
28-day

152/154 (98.7%)
151/154 (98.1%)
133/154 (86.4%)

108/110 (98.2%)
107/110 (97.3%)
94/110 (85.5%)

46/46 (100%)
45/46 (97.8%)
41/44 (89.1%)

306/310 (98.7%)
303/310 (97.7%)
268/310 (86.5%)

ITT population, PCR corrected
7-day
152/154 (98.7%)
14-day
151/154 (98.1%)
28-day
145/154 (94.2%)

108/110 (98.2%)
107/110 (97.3%)
103/110 (93.6%)

46/46 (100.0%)
45/46 (97.8%)
43/46 (93.5%)

306/310 (98.7%)
303/310 (97.7%)
291/310 (93.9%)

PP population
7-day
14-day
28-day

105/105 (100%)
105/105 (100%)
92/105 (87.6%)

44/44 (100%)
43/43 (100%)
39/43 (90.7%)

293/293 (100%)
292/292 (100%)
258/291 (88.7%)

144/144 (100%)
144/144 (100%)
127/143 (88.8%)

Total
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Table 3 Adverse events (after baseline but before recurrence) occurring in more than 10% of patients treated
with co-artemether, irrespective of cause
Adverse event

Bodyweight group

Patients: n (%)
Cough
Anemia
Vomiting
Anorexia
Diarrhea
Hepatomegaly
Splenomegaly
Upper respiratory tract infection

Total

5—<10 kg

10—<15 kg

15—≤25 kg

154
44
41
25
17
20
10
11
19

110
28
21
12
15
10
12
13
6

46
5
9
8
5
3
5
2
0

(100)
(28.6)
(26.6)
(16.2)
(11.0)
(13.0)
(6.5)
(7.1)
(12.3)

diarrhea (Table 3). Some differences in adverse
events were seen between bodyweight groups but,
since these were generally mild, differences were
not considered to be clinically signiﬁcant. In total,
76/310 (24.5%) children had adverse events that
were thought by the investigator to be possibly related to the study medication (Table 4). The most
frequent categories included gastrointestinal disorders (especially vomiting and diarrhea) and hematologic disorders (anemia and eosinophilia).
Only six patients (1.9%) had severe adverse
events; two had anemia and one each had gastroenteritis, viral hepatitis, urticaria and malaria (recurrence on day 28). Only urticaria was considered to
be drug related. The child with severe gastroenteritis developed gastroenteritis and died after hospital
discharge, but this death was not considered to be
related to study medication.

(100)
(25.5)
(19.1)
(10.9)
(13.6)
(9.1)
(10.9)
(11.8)
(5.5)

(100)
(10.9)
(19.6)
(17.4)
(10.9)
(6.5)
(10.9)
(4.3)
(0)

310
77
71
45
37
33
27
26
25

(100)
(24.8)
(22.9)
(14.5)
(11.9)
(10.6)
(8.7)
(8.4)
(8.1)

Hemoglobin levels decreased from baseline to
day 3 and then increased to day 28, consistent with
resolution of the malaria infection. Most of the
hematologic criteria shifted toward normal from
baseline by day 28, with the exception of neutrophil
counts. Approximately half of the patients with
normal neutrophil counts at baseline shifted to low
counts. A total of 45/310 (14.5%) had neutrophil
counts of <109 /l at some point during the study.
In most cases, the low counts were transient and
occurred at day 0 or day 3, but 13 (4.2%) patients
had isolated neutrophil counts of <109 /l at day 28.
Eight patients had neutrophil counts corresponding
to NIH CTC grades 3 and 4. All grade 4 counts (one
at baseline and two at day 28) had at least one
subsequent count that was normal, as did three of
grade 3 counts out of ﬁve patients. The remaining
two patients with NIH CTC grade 3 neutrophil

Table 4 Adverse events (occurring after baseline but before recurrence in >2% of patients) suspected by the
investigator to be related to study medication (safety population)
Adverse event

Bodyweight group
5—<10 kg

10—<15 kg

15—≤25 kg

Patients: n (%)

154 (100)

110 (100)

46 (100)

310 (100)

Hematological
Anemia
Eosinophilia

8 (5.2)
6 (3.9)

6 (5.5)
6 (5.5)

1 (2.2)
0 (0)

15 (4.8)
12 (3.9)

10 (6.5)
5 (3.2)
2 (1.3)

0 (0)
5 (4.5)
3 (2.7)

4 (8.7)
1 (2.2)
0 (0.0)

14 (4.5)
11 (3.5)
5 (1.6)

7 (4.5)
1 (0.6)

5 (4.5)
2 (1.8)

1 (2.2)
1 (2.2)

13 (4.2)
4 (1.3)

Skin/subcutaneous tissue disorders
Rash
6 (3.9)

3 (2.7)

0 (0)

9 (2.9)

Gastrointestinal
Vomiting
Diarrhea
Constipation
Nervous system disorders
Clonus
Hyperreﬂexia

Total
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counts had no follow-up evaluations. The low
neutrophil counts at days 0 and 3 (and in one case
at day 28, where the patient had a new malaria infection) were probably malaria-related. Malaria is
known to be associated with neutropenia, possibly
due to splenic sequestration of neutrophils. The
signiﬁcance of the low neutrophil counts observed
on day 28 is unclear, but, as with cases seen at
day 0 or 3, there did not appear to be any clinical
consequences, in terms of infections. Also, the
observed neutrophil counts should be considered
in the light of the reported lower counts in healthy
Africans, particularly very young children, than in
Caucasian patients (Lugada et al., 2004).
Electrocardiographic changes included a decrease in heart rate from baseline, with slight
increases in PR, QRS and QT intervals. The QTc
interval (corrected by Bazett’s formula) showed
slight, clinically non-signiﬁcant increases (<30 msec
in 211/273, 77.3% and >60 msec in 11/273, 4%), and
mean and median values at day 3 remained within
the normal range. One patient (0.4%) with normal
QTc at baseline had a slightly prolonged QTc on day
3 (403 to 454 msec), and 19/273 patients (7.0%)
were borderline. Two of three children with QTc
prolongation at baseline reverted to normal by day
3. Children with borderline prolonged QTc at baseline remained borderline at day 3. No patient had
a QTc interval >500 msec. Shift analysis (based on
Fridericia’s formula) showed no patient with QTc
prolongation at baseline or day 3.

and their desire to have a single global dosing regimen for this medication, the underlying purpose
of this study has been to determine whether or not
the safety proﬁle of the six-dose co-artemether
regimen will permit it to replace the four-dose
regimen. Studies in Southeast Asia have already
shown that the six-dose co-artemether regimen is
more effective than the four-dose regimen, while
remaining equally safe and well tolerated (Lefèvre
et al., 2001; Van Vugt et al., 1999). However, the
six-dose regimen has not previously been studied
in children weighing <10 kg.
An open-label, non-comparative design was
adopted because no suitable comparator was
available. In our study, co-artemether treatment
demonstrated good efﬁcacy, with corrected cure
rates greater than 90% in all bodyweight groups,
irrespective of the level of parasitemia and body
temperature.
In the treatment of malaria, background immunity to the malarial parasite from repeated
infections usually acts synergistically with antimalarial drugs to achieve better cure rates than
in non-immune individuals, such as young children
(Ezzet et al., 1998). In our study, the six-dose
co-artemether regimen was equally effective in
partially immune infants and those who were
likely to be non-immune on the basis of their age
and malaria history. The response to treatment
was rapid in all groups, with a median time to
fever clearance of less than eight hours (although
some of the effect may have been attributable
to acetaminophen). The median time to parasite
clearance was approximately 30 hours. The rapid
parasite clearance and the antigametocyte effects
of the six-dose regimen are compatible with
decreased risk of developing drug resistance.
Almost half the patients weighed 5—<10 kg and
the treatment regimen was well tolerated. This was
despite these patients receiving higher doses, on
a mg/kg basis, than those in higher bodyweight
groups. Most of the adverse events, which were
mild, had been reported previously (Von Seidlein
et al., 1998) and were indicative of symptoms of
malaria or other infections common in this population. Only one patient had a serious adverse
event (urticaria) considered to be related to the
study medication. The patient was hospitalized and
co-artemether treatment was withdrawn. The urticaria resolved after four days.
No signiﬁcant abnormal laboratory values associated with co-artemether were recorded. Due
to the chemical similarity between lumefantrine
and the aryl-amino group of halofantrine (which is
known to cause delayed ventricular repolarization
manifested by QTc interval prolongation), the

4. Discussion
The primary aim was to assess the safety of the sixdose co-artemether regimen in the treatment of
falciparum malaria in children and infants weighing 5—25 kg, in order to allow a comparison with
previous studies using four doses of co-artemether
in pediatric patients weighing 5—25 kg (Hatz et al.,
1998; Irion et al., 1997; Von Seidlein et al., 1997,
1998). The four-dose regimen appears sufﬁcient to
provide 28-day cure rates greater than 95% in regions where patients were partially immune and in
areas without multidrug resistance (Lefèvre et al.,
2001). However, higher dosages (e.g. six doses given
over 3 days) are required to give similarly high cure
rates in regions such as Southeast Asia, with drugresistant P. falciparum strains, since the four-dose
regimen gives suboptimal (<85%) cure rates under
these circumstances (Lefèvre et al., 2001; Van Vugt
et al., 1999).
In view of the concerns expressed by the WHO
about the short- and long-term effectiveness and
safety of the four-dose regimen of co-artemether,
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possibility of a cardiotoxic effect of lumefantrine
was investigated. These studies, both in vitro
and in vivo, showed that lumefantrine lacked
the cardiotoxicity of halofantrine (Bakshi et al.,
2000; Bindschedler et al., 2000; Lefèvre et al.,
2001; Van Vugt et al., 1999). No patient had a
QTc interval >500 msec; the occasional increases
of >60 msec occurred mostly in the youngest
infants (aged <2 years). QTc changes were comparable with those reported with the four-dose
regimen. The Committee for Proprietary Medicinal
Products (1997) suggested that prolongation of a
QTc increase of >60 msec raises concerns about the
potential risk of arrhythmias, but the applicability
of these adult values to small children with malaria
is unknown. In high doses, artemether did not give
rise to prolonged QTc intervals (Price et al., 1999).
Moreover, signiﬁcant prolongation of the QTc interval during treatment with other antimalarial drugs
(chloroquine, sulfadoxine—pyrimethamine) was
considered to be independent of treatment, but
weakly correlated with baseline parasitemia and
pyrexia (Von Seidlein et al., 1997). In view of the
ﬁndings of these and earlier studies, it seems that
the six-dose regimen of co-artemether is unlikely to
be associated with cardiotoxicity. The WHO report
of an informal consultation of international malaria
experts on the use of anti-malarial drugs (WHO,
2000) concluded ‘there is no evidence of increased toxicity with the 6-dose as compared to
the 4-dose regimen of co-artemether in malarial
areas’.

5. Conclusions
The six-dose regimen of co-artemether is a safe
and well-tolerated treatment for acute falciparum malaria in African pediatric patients weighing 5—25 kg. Treatment results in rapid clearance of parasitemia and fever, gives high cure
rates, and appears to be equally effective in nonimmune and partially immune infants. The sixdose co-artemether regimen, therefore, fulﬁls the
requirements of the WHO for an effective and
safe therapy of falciparum malaria in infants and
children who are most susceptible to develop
malaria.
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